SCHEMBL24708803

SCHEMBL24708803

O=c1n(CCCCc2ccccc2)c2ccccc2n1C1CCN(CCCCCc2ccccc2)CC1

nearest known ligand 0.98

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CACNA1G O43497 4/20 0.98
▸ CACNA1H O95180 4/20 0.98
▸ SIGMAR1 Q99720 7/20 0.57
▸ MEN1 O00255 1/20 0.55
▸ TP53 P04637 1/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ CYP2D6 P10635 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ DRD2 P14416 1/20 0.53
▸ DRD4 P21917 1/20 0.53
▸ DRD3 P35462 1/20 0.53
▸ CCR3 P51677 1/20 0.52
▸ C5AR1 P21730 2/20 0.51
▸ OPRL1 P41146 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24709347 1.00 CACNA1G (0.98) CACNA1GCACNA1HSIGMAR1MEN1TP53
SCHEMBL30079694 0.99 CACNA1G (1.00) CACNA1GCACNA1HSIGMAR1MEN1TP53
SCHEMBL24708724 0.99 CACNA1G (1.00) CACNA1GCACNA1HSIGMAR1MEN1TP53
SCHEMBL24709558 0.98 CACNA1G (0.98) CACNA1GCACNA1HSIGMAR1MEN1TP53
SCHEMBL24709104 0.98 CACNA1G (0.98) CACNA1GCACNA1HSIGMAR1MEN1TP53
SCHEMBL24709556 0.93 CACNA1G (0.89) CACNA1GCACNA1HSIGMAR1MEN1TP53
SCHEMBL27206859 0.93 CACNA1G (0.89) CACNA1GCACNA1HSIGMAR1MEN1TP53
SCHEMBL24708739 0.93 CACNA1G (0.89) CACNA1GCACNA1HSIGMAR1MEN1TP53
SCHEMBL24708800 0.93 CACNA1G (0.85) CACNA1GCACNA1HSIGMAR1CYP3A4CYP2D6
SCHEMBL24709338 0.92 CACNA1G (0.87) CACNA1GCACNA1HSIGMAR1MEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287019-A1 T-TYPE CALCIUM CHANNEL BLOCKER FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2024-08-29 — — US disclosed
EP-4353713-A1 T-TYPE CALCIUM CHANNEL BLOCKER Kinki University (JP) 2024-04-17 — — EP disclosed
WO-2022260016-A1 T-TYPE CALCIUM CHANNEL BLOCKER 学校法人近畿大学 2022-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287019-A1 T-TYPE CALCIUM CHANNEL BLOCKER CACNA1G, CACNA1I, CACNA1H CACNA1G 1/4885CACNA1H 3/4885SIGMAR1 2729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback